Head and neck cancer, excluding thyroid
Invited Discussant 1045PD, 1046PD and 1047PD
Date
09 Sep 2017Session
Head and neck cancer, excluding thyroidPresenters
Joel GuigayAuthors
J. GuigayAuthor affiliations
- -, Centre Antoine Lacassagne, 6100 - Nice/FR
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
4519 - Adjuvant androgen deprivation therapy for high-risk androgen receptor-positive salivary duct carcinoma
Presenter: Wim Boxtel
Session: Head and neck cancer, excluding thyroid
Resources:
Abstract
4589 - Overexpression of the c-MET proto-oncogene in salivary duct carcinoma patients
Presenter: Carla Herpen
Session: Head and neck cancer, excluding thyroid
Resources:
Abstract
2425 - Mammary Analogue Secretory Carcinoma (MASC): clinical characteristics in 28 ETV6-NTRK3 fusion gene confirmed patients.
Presenter: Eline Boon
Session: Head and neck cancer, excluding thyroid
Resources:
Abstract
5137 - RetroSpective cohort stUdy of PD-L1 expression in REcurrent and/or MEtastatic squamous cell carcinoma of the Head and Neck (SUPREME-HN)
Presenter: Sara Pai
Session: Head and neck cancer, excluding thyroid
Resources:
Abstract
3501 - Relationship between PD-L1 expression and survival in head and neck squamous cell carcinoma (HNSCC) patients (pts)
Presenter: Michael Stokes
Session: Head and neck cancer, excluding thyroid
Resources:
Abstract
3668 - The ELAN-ONCOVAL (ELderly heAd and Neck cancer-Oncology eValuation) study: Evaluation of the feasibility of a suited geriatric assessment for use by oncologists to classify patients as fit or unfit.
Presenter: Cecile Mertens
Session: Head and neck cancer, excluding thyroid
Resources:
Abstract
2588 - A phase 1, multicenter, open-label, dose-escalation, combination study of RM-1929 and photoimmunotherapy in patients with recurrent head and neck cancer
Presenter: Samith Thomas Kochuparambil
Session: Head and neck cancer, excluding thyroid
Resources:
Abstract
4798 - First-line Paclitaxel plus Carboplatin with/without Bevacizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma: a Multicenter, Randomized, Open-label, Phase II Trial
Presenter: Li Zhang
Session: Head and neck cancer, excluding thyroid
Resources:
Abstract
2445 - Refining staging system for nasopharyngeal carcinoma treated with intensity-modulated radiation therapy
Presenter: Victor Lee
Session: Head and neck cancer, excluding thyroid
Resources:
Abstract
859 - A New Classification for Nasopharyngeal Carcinoma
Presenter: Hung Chun Cheng
Session: Head and neck cancer, excluding thyroid
Resources:
Abstract